What is Levicept?
Levicept is a biopharmaceutical company dedicated to addressing the unmet needs of individuals suffering from chronic pain, particularly that associated with osteoarthritis. The company's core mission is to provide effective and well-tolerated analgesic alternatives that mitigate the risks of prolonged opiate use and the adverse effects commonly linked to non-steroidal anti-inflammatory drugs (NSAIDs). By focusing on advanced scientific research and rigorous clinical trials, Levicept aims to establish itself as a leader in safer, more sustainable pain management solutions for patients seeking relief from debilitating chronic pain.
How much funding has Levicept raised?
Levicept has raised a total of $16M across 1 funding round:
Series A
$16M
Series A (2014): $16M with participation from Advent Life Sciences, Index Ventures, and Gilde Healthcare
Key Investors in Levicept
Advent Life Sciences
Advent Life Sciences is a venture capital firm specializing in early-stage life science companies, likely focusing on therapeutic innovation and platform technologies within the healthcare sector.
Index Ventures
Index Ventures is a global venture capital firm that invests in entrepreneurs from seed to IPO, with a broad interest in technology and healthcare companies aiming to disrupt established markets.
Gilde Healthcare
Gilde Healthcare is a specialized investment firm focused on the healthcare sector, managing venture and growth capital to support companies developing innovative therapies and healthcare solutions.
What's next for Levicept?
With the recent influx of major strategic investment, Levicept is poised for a significant scaling phase. The company's focus on developing safer analgesic solutions for chronic pain positions it favorably within a growing market segment. Future endeavors will likely involve advancing its therapeutic candidates through late-stage clinical trials, seeking regulatory approvals, and establishing robust commercialization strategies. The backing from prominent investors suggests confidence in Levicept's scientific approach and its potential to disrupt the current pain management landscape, offering a much-needed alternative to existing treatments.
See full Levicept company page
